Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296138 · ClinicalTrials.gov registry record · Phase 3
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,903
- Enrollment target
- 20
- Study locations
NCT02296138 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,903 participants, above the 937-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (743% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02296138, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,903 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.
Conditions Studied
Interventions
- DRUG tiotropium
- DRUG olodaterol
Study Locations (20)
Florida
- 1237.19.10029 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.19.10106 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.19.10020 Boehringer Ingelheim Investigational Site - Orlando
- 1237.19.10000 Boehringer Ingelheim Investigational Site - St. Petersburg
- 1237.19.10135 Boehringer Ingelheim Investigational Site - St. Petersburg
- 1237.19.10145 Boehringer Ingelheim Investigational Site - Tamarac
- 1237.19.10066 Boehringer Ingelheim Investigational Site - Tampa
Alabama
- 1237.19.10039 Boehringer Ingelheim Investigational Site - Andalusia
- 1237.19.10009 Boehringer Ingelheim Investigational Site - Birmingham
- 1237.19.10077 Boehringer Ingelheim Investigational Site - Florence
- 1237.19.10115 Boehringer Ingelheim Investigational Site - Jasper
California
- 1237.19.10110 Boehringer Ingelheim Investigational Site - Lincoln
- 1237.19.10118 Boehringer Ingelheim Investigational Site - Los Angeles
- 1237.19.10074 Boehringer Ingelheim Investigational Site - Poway
Arizona
- 1237.19.10069 Boehringer Ingelheim Investigational Site - Flagstaff
- 1237.19.10085 Boehringer Ingelheim Investigational Site - Peoria
Colorado
- 1237.19.10157 Boehringer Ingelheim Investigational Site - Lafayette
- 1237.19.10142 Boehringer Ingelheim Investigational Site - Wheat Ridge
Connecticut
- 1237.19.10133 Boehringer Ingelheim Investigational Site - Norwalk
- 1237.19.10093 Boehringer Ingelheim Investigational Site - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,903 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2017-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296138
The ClinicalTrials.gov registry entry for NCT02296138 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,903 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 937-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (743% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which tiotropium is the first listed.
NCT02296138 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT02296138 about?
NCT02296138 is a clinical study titled "Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.". The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.
What is the current status of trial NCT02296138?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,903 participants. The study started on 2015-01-13. Estimated completion is 2017-03-29.
What conditions does trial NCT02296138 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT02296138?
The interventions under investigation include: tiotropium (DRUG), olodaterol (DRUG).
Who is sponsoring clinical trial NCT02296138?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296138 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.